Triose Phosphate Isomerase: Difference between revisions

No edit summary
No edit summary
Line 66: Line 66:


== Disease ==
== Disease ==
<Structure load='2ypi' size='300' frame='true' align='right' scene='Triose_Phosphate_Isomerase/Glu_104_1/6'/>
<Structure load='2ypi' size='350' frame='true' align='right' scene='Triose_Phosphate_Isomerase/Glu_104_1/6'/>
'''Triose Phosphate Isomerase Deficiency''': Initially described in 1965,  TPI deficiency is an autosomal recessive inherited disorder with characteristics ranging from chronic haemolytic anaemia, increased susceptibility to infections, severe neurological dysfunction, and often times death in early childhood.<ref>PMID:10916682</ref> The effects of TPI deficiency are most closely linked to a point mutation at the <scene name='Triose_Phosphate_Isomerase/Glu_104_1/6'>Glu104</scene> residue which results in the <scene name='Triose_Phosphate_Isomerase/Glu104asp3/2'>Glu104Asp</scene> mutation. A common marker for TPI deficiency is the increased accumulation of DHAP in erythrocyte extracts as a result in the inability of the mutant enzyme to catalyze the isomerization to GAP. Recent evidence has indicated that the point mutation does not prove detrimental to the rate of catalysis of the enzyme, but rather effects the ability of the enzyme to dimerize.<ref>PMID:17183658</ref>
'''Triose Phosphate Isomerase Deficiency''': Initially described in 1965,  TPI deficiency is an autosomal recessive inherited disorder with characteristics ranging from chronic haemolytic anaemia, increased susceptibility to infections, severe neurological dysfunction, and often times death in early childhood.<ref>PMID:10916682</ref> The effects of TPI deficiency are most closely linked to a point mutation at the <scene name='Triose_Phosphate_Isomerase/Glu_104_1/6'>Glu104</scene> residue which results in the <scene name='Triose_Phosphate_Isomerase/Glu104asp3/2'>Glu104Asp</scene> mutation. A common marker for TPI deficiency is the increased accumulation of DHAP in erythrocyte extracts as a result in the inability of the mutant enzyme to catalyze the isomerization to GAP. Recent evidence has indicated that the point mutation does not prove detrimental to the rate of catalysis of the enzyme, but rather effects the ability of the enzyme to dimerize.<ref>PMID:17183658</ref>


Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

Gregg Snider, Stephen Everse, Eran Hodis, David Canner, Eric Martz, Michal Harel, Alexander Berchansky, Jane S. Richardson, Angel Herraez